Loading
Interviews with 53 Iranian cancer specialists describe how economic sanctions led to shortages, lower-quality imported materials, higher prices, lost staff and delays in cancer diagnosis and treatment.
In-depth qualitative interviews with 53 experts, including clinical and basic science specialists chosen by purposeful sampling, analysed by content analysis in MAXQDA 2020. The 900 codes were grouped into input, process and output categories with 13 subcategories.
Sanctions on Iran exempt medicines and food in principle, but these clinicians report that cancer patients still meet shortages, substitutions and delays, which is the practical context for Iran's push to make cancer medicines itself.
Shares Iran Food and Drug Administration (IFDA), Most of the world has almost no cancer care.
Shares Global oncology and access in low- and middle-income countries, Most of the world has almost no cancer care.
Shares Global oncology and access in low- and middle-income countries, Most of the world has almost no cancer care.
Shares Global oncology and access in low- and middle-income countries, Most of the world has almost no cancer care.
Shares Global oncology and access in low- and middle-income countries, Most of the world has almost no cancer care.
Shares Iran Food and Drug Administration (IFDA), Cancer Institute of Iran, Imam Khomeini Hospital Complex.
Shares Global oncology and access in low- and middle-income countries, Most of the world has almost no cancer care.
Shares Global oncology and access in low- and middle-income countries, Most of the world has almost no cancer care.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/